GLUE | Monte Rosa Therapeutics, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	6.41 - 7.14
52 Week Range	3.21 - 12.40
Beta	1.07
Implied Volatility	122.62%
IV Rank	13.54%
Day's Volume	2,568,441
Average Volume	2,662,276
Shares Outstanding	61,436,700
Market Cap	425,756,331
Sector	Healthcare
Industry	Biotechnology
IPO Date	2021-06-24

Valuation
Profitability
Growth
Health
P/E Ratio	-3.89
Forward P/E Ratio	N/A
EPS	-1.78
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	133
Country	USA
Website	GLUE

Monte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. It develops an oral molecular glue degrader for GSPT1, a translational termination factor and degron-containing protein for the treatment of Myc-driven cancers. The company also develops CDK2 to treat ovarian, uterine, and breast cancers; NEK7 for the treatment of inflammatory diseases, such as Crohn's disease, neurodegenerative disease, diabetes, and liver disease; VAV1, a target protein for autoimmune diseases; and BCL11A, a therapeutically-relevant protein in hemoglobinopathies. Monte Rosa Therapeutics, Inc. was incorporated in 2019 and is headquartered in Boston, Massachusetts.

GLUE's peers: AADI, ACET, ALEC, ARQT, ARVN, BCAB, BCYC, CCCC, CDXS, CGEM, CLGN, CLLS, CLSD, CNTA, CORT, DNLI, DSGN, DYN, ENTA, ERAS, EVAX, FGEN, FHTX, CMPX, GBIO, GHRS, GLTO, NKTX, LYEL, SANA, HOWL, IKNA, STOK, STTK, KYMR, NRIX, GRCL, THRX, GNLX, IFRX, IGMS, IMAB, IMCR, IMRX, IMUX, INBX, INKT, IOBT, IPSC, ITOS, IVA, KPTI, KROS, KURA, KZR, MDWD, MDXG, MGNX, MIST, MOLN, MTNB, NVCT, OLMA, PHVS, PMVP, PRLD, RANI, RAPT, RGNX, RLAY, RLYB, RVMD, SEER, SLDB, SLN, SRRK, SWTX, SYBX, TARS, TNGX, TNYA, TPST, TRDA, TSHA, TYRA, VALN, VERA, VIGL, VIRX, VOR, XNCR, ZNTL, BLTE, HLVX, THRD, PMN, LSTA, PROK, NAMS, OABI, ZVRA, GRI

*Chart delayed

Analyzing fundamentals for GLUE we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is very bad and Health is very weak. For more detailed analysis please see GLUE Fundamentals page.

Watching at GLUE technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, but short-term trend is bearish. More technicals details can be found on GLUE Technicals page.